Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 7/20 | 0.62 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
| ▸ | HTR5A | P47898 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 4/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8435916 | 0.85 | KEAP1 (0.64) | MTNR1AKEAP1NFE2L2MTNR1B | |
| SCHEMBL10222343 | 0.85 | MTNR1A (0.48) | MTNR1ACYP2A6CA2 | |
| SCHEMBL8431821 | 0.84 | MTNR1A (0.59) | MTNR1ACYP2A6HTR5ACA2MTNR1B | |
| SCHEMBL8605628 | 0.84 | MTNR1A (0.59) | MTNR1ACYP2A6KEAP1NFE2L2HTR5A | |
| SCHEMBL13201460 | 0.83 | MTNR1A (0.51) | MTNR1ACYP2A6KEAP1NFE2L2HTR5A | |
| Hydrochloric Acid SCHEMBL8882742 | 0.83 | MTNR1A (0.58) | MTNR1ACYP2A6HTR5ACA2MTNR1B | |
| SCHEMBL10064416 | 0.83 | MTNR1A (0.53) | MTNR1ACYP2A6KEAP1NFE2L2HTR5A | |
| SCHEMBL8431982 | 0.83 | CYP2A6 (0.63) | MTNR1ACYP2A6KEAP1NFE2L2HTR5A | |
| SCHEMBL8037709 | 0.82 | MTNR1A (0.56) | MTNR1ACYP2A6HTR5ACA2MTNR1B | |
| SCHEMBL10266973 | 0.81 | CA2 (0.60) | MTNR1ACYP2A6KEAP1NFE2L2CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088791-B2 | Antibacterial agents | Biots Scientific Management Pty Ltd (AU) | 2012-01-03 | — | — | US | disclosed |
| US-20100173933-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173933-A1 | ANTIBACTERIAL AGENTS | ALK, ROS1, NOX1 | MTNR1A 332/4885CYP2A6 892/4885KEAP1 1587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.